Ferring Pharmaceuticals will acquire Gameto, a cell engineering company focused on fertility treatments, in a deal valued at up to $1.38 billion. The move signals continued consolidation in reproductive biotech, where platform IP and cell engineering capabilities are increasingly central to next-generation fertility programs. The transaction is positioned as a way for Ferring to expand its pipeline into newer cell-based and engineering-driven fertility approaches. Gameto’s Fertilo platform is expected to add technical depth across fertility biology and product development, potentially accelerating preclinical-to-clinical translation. No additional trial readouts were included in the announcement, but the size of the offer suggests Ferring views fertility as strategically important—particularly as companies compete for differentiated platform capabilities rather than single-mechanism assets.